INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR

Impact · against what's priced in

Capricor Therapeutics faces a catastrophic loss of value following an unfavorable FDA benefit-risk assessment and a negative AdCom vote regarding deramiocel. The subsequent class action lawsuit adds legal liability to a company whose core drug candidate has been deemed ineffective by regulators.

CAPR−1.00: No priced-in read yet

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR

What matters in this story

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR

What matters in this story

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

How each ticker is affected

Track these names every morning.

QFIN Investors Have Opportunity to Lead Qfin Holdings, Inc. Securities Fraud Lawsuit with SBS Law

A little-known biotech's high-stakes cancer bet just paid off and its shares doubled

I-Mab Picks Givastomig Dose After Promising Gastric Cancer Data, Aligns With FDA

ANAVEX LIFE SCIENCES DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR

What matters in this story

Next reads from the same story arc

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR

What matters in this story

Next reads from the same story arc

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

How each ticker is affected

Track these names every morning.

QFIN Investors Have Opportunity to Lead Qfin Holdings, Inc. Securities Fraud Lawsuit with SBS Law

A little-known biotech's high-stakes cancer bet just paid off and its shares doubled

I-Mab Picks Givastomig Dose After Promising Gastric Cancer Data, Aligns With FDA

ANAVEX LIFE SCIENCES DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL